The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies

Inhibition of COX-2 in Colon Cancer Modulates Tumor Growth and MDR-1 Expression to Enhance Tumor Regression in Therapy-Refractory Cancers In Vivo

(2015) Mahbuba Rahman et al.   NEOPLASIA

Design, synthesis, cytotoxic evaluation and tubulin inhibitory activity of 4-aryl-5-(3,4,5-trimethoxyphenyl)-2-alkylthio-1H-imidazole derivatives

(2013) Amir Assadieskandar et al.   BIOORGANIC & MEDICINAL CHEMISTRY

PTGS2 (Cyclooxygenase-2) Expression and Survival among Colorectal Cancer Patients: A Systematic Review

(2013) A. T. Kunzmann et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status

(2013) Reiko Nishihara et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer

(2013) Enric Domingo et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib

(2013) Robert Ramer et al.   JOURNAL OF LIPID RESEARCH

Synthesis, molecular docking study, and anticancer activity of triaryl-1,2,4-oxadiazole

(2013) Parisa Miralinaghi et al.   MEDICINAL CHEMISTRY RESEARCH

Design, synthesis, and cytotoxic activities of new 2,4,5-triarylimidazoles

(2012) A. Zarghi et al.   MEDICINAL CHEMISTRY RESEARCH

Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms

(2012) Whay Kuang Chia et al.   Nature Reviews Clinical Oncology

Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer Survival

(2012) Xiaoyun Liao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epigenetic deregulation of the COX pathway in cancer

(2012) Inês Cebola et al.   PROGRESS IN LIPID RESEARCH

COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status

(2011) Annika Gustafsson Asting et al.   BMC CANCER

Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells

(2011) Kim et al.   International Journal of Nanomedicine

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

(2011) Rassoul Dinarvand et al.   International Journal of Nanomedicine

Design and synthesis of new 2,4,5-triarylimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors

(2011) A. Zarghi et al.   MEDICINAL CHEMISTRY RESEARCH

The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer

(2011) Dingzhi Wang et al.   Cancers

Targeting COX-2 expression by natural compounds: A promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy

(2010) Claudia Cerella et al.   BIOCHEMICAL PHARMACOLOGY

COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-β, IL-10 and Ki67

(2010) Elin Richardsen et al.   Cancer Epidemiology

Overexpression of COX-2 in Celecoxib-Resistant Breast Cancer Cell Lines

(2010) Balraj Singh et al.   JOURNAL OF SURGICAL RESEARCH

Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines

(2010) Claudia Bocca et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor

(2009) Domenico D'Arca et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Overexpression of ELAV-like Protein HuR is Associated with Increased COX-2 Expression in Atrophy, High-grade Prostatic Intraepithelial Neoplasia, and Incidental Prostate Cancer in Cystoprostatectomies

(2008) Francesca Barbisan et al.   EUROPEAN UROLOGY

Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA–PEG–folate conjugate

(2008) Farnaz Esmaeili et al.   JOURNAL OF DRUG TARGETING

Cyclin-dependent kinases and cell-cycle transitions: does one fit all?

(2008) Helfrid Hochegger et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Selective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo

(2008) Xuan-Fu Xu et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE